• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Baxalta - Articles and news items


Shire and Baxalta combine to create a global leader in rare diseases

Industry news / 3 June 2016 / Victoria White, Digital Content Producer

Shire and Baxalta have combined businesses, creating a leading global company focused on rare diseases and other highly specialised conditions…

BAX 826

First patient dosed in BAX 826 haemophilia A Phase I trial

Industry news / 4 March 2016 / Victoria White

BAX 826 is a next-generation rFVIII treatment based on the full length Advate that uses proprietary polysialic acid technology to extend its circulating half-life…


MAA submitted for haemophilia A treatment, Adynovi

Industry news / 2 March 2016 / Victoria White

Adynovi is an extended circulating half-life recombinant Factor VIII treatment, for paediatric, adolescent and adult patients with haemophilia A…


Marketing Authorisation granted for Oncaspar as combination therapy in ALL

Industry news / 19 January 2016 / Victoria White

With this authorisation, Oncaspar will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells…


Shire to acquire Baxalta in $32 billion deal

Industry news / 11 January 2016 / Victoria White

The combination of Shire and Baxalta will create the number one rare diseases platform in revenue and pipeline depth…


Adynovate meets endpoint in paediatric Haemophilia A study

Industry news / 21 December 2015 / Victoria White

The study enrolled 73 previously-treated patients with severe haemophilia A younger than 12 years of age and assessed the treatment’s haemostatic efficacy in prophylaxis and treatment of bleeding episodes…


FDA approves Vonvendi for the treatment of von Willebrand Disease

Industry news / 9 December 2015 / Victoria White

Vonvendi [von Willebrand factor (Recombinant)] is the first and only recombinant treatment for adults living with von Willebrand Disease (VWD)…


Baxalta to initiate clinical trial of BAX 826 in haemophilia A

Industry news / 20 November 2015 / Victoria White

Baxalta expects to begin treating participants in the open-label, dose-finding study by early 2016…

BAX 826

FDA approves haemophilia A treatment Adynovate

Industry news / 16 November 2015 / Victoria White

Adynovate has been shown to reduce the number of bleeding episodes during routine care…


EC grants Marketing Authorisation for Obizur

Industry news / 13 November 2015 / Victoria White

Obizur is the first recombinant porcine sequence FVIII treatment available in Europe to treat acquired haemophilia A…


Investigational Enbrel biosimilar CHS-0214 meets primary endpoints

Industry news / 10 November 2015 / Victoria White

CHS-0214 met its primary endpoints in a Phase 3 study in patients with moderate-to-severe chronic plaque psoriasis…


First patient enrolled in Phase 2 study of Onivyde in pancreatic adenocarcinoma

Industry news / 27 October 2015 / Victoria White

The start-up of this study resulted in $62.5M of milestone payments to Merrimack from Baxalta…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +